Pfizer (NYSE:PFE) Given a $55.00 Price Target at UBS Group

UBS Group set a $55.00 target price on Pfizer (NYSE:PFE – Get Rating) in a research report report published on Wednesday morning, Borsen Zeitung reports.

Several other analysts have also commented on PFE. The Goldman Sachs Group raised shares of Pfizer from a neutral rating to a buy rating and lifted their price target for the company from $47.00 to $60.00 in a research report on Tuesday, December 13th. Morgan Stanley lifted their price objective on shares of Pfizer from $51.00 to $53.00 and gave the stock an equal weight rating in a research report on Wednesday, December 14th. SVB Leerink lifted their price objective on shares of Pfizer from $48.00 to $49.00 and gave the stock a market perform rating in a research report on Thursday, November 3rd. Barclays boosted their price target on shares of Pfizer from $44.00 to $49.00 and gave the company an equal weight rating in a research report on Wednesday, November 2nd. Finally, JPMorgan Chase & Co. set a $50.00 price target on shares of Pfizer in a research report on Wednesday. Seven analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Pfizer has a consensus rating of Hold and a consensus target price of $53.00.

Pfizer Price Performance

NYSE:PFE opened at $45.00 on Wednesday. Pfizer has a 52 week low of $41.44 and a 52 week high of $56.32. The company has a quick ratio of 1.37, a current ratio of 1.59 and a debt-to-equity ratio of 0.35. The stock has a market capitalization of $252.60 billion, a PE ratio of 8.65, a price-to-earnings-growth ratio of 1.13 and a beta of 0.67. The stock’s 50-day moving average price is $49.97 and its 200-day moving average price is $48.33.

Pfizer (NYSE:PFE – Get Rating) last issued its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported $1.78 earnings per share for the quarter, beating analysts’ consensus estimates of $1.47 by $0.31. The firm had revenue of $22.64 billion for the quarter, compared to analyst estimates of $21.04 billion. Pfizer had a net margin of 29.81% and a return on equity of 43.95%. As a group, equities analysts expect that Pfizer will post 6.46 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 3rd. Stockholders of record on Friday, January 27th will be given a $0.41 dividend. The ex-dividend date is Thursday, January 26th. This is a positive change from Pfizer’s previous quarterly dividend of $0.40. This represents a $1.64 annualized dividend and a dividend yield of 3.64%. Pfizer’s dividend payout ratio is currently 30.77%.

Institutional Trading of Pfizer

Large investors have recently modified their holdings of the business. Lam Group Inc. purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $25,000. Steward Financial Group LLC lifted its stake in shares of Pfizer by 315.3% during the second quarter. Steward Financial Group LLC now owns 544 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 413 shares during the period. Worth Asset Management LLC purchased a new position in shares of Pfizer during the first quarter valued at approximately $29,000. Goodman Advisory Group LLC purchased a new position in Pfizer during the second quarter worth approximately $32,000. Finally, Karp Capital Management Corp purchased a new position in shares of Pfizer in the 3rd quarter worth $27,000. 67.62% of the stock is currently owned by institutional investors and hedge funds.

About Pfizer

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.